Trial 7H-13-1


Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.

Type: Treatment
Phase: Phase I/II
Status: Not Open (Closed)
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Grace Facio, Coordinator, Charlean Ketchens, Coordinator, Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Gina Tse, R.N., Eduardo Mejia, D.M., Bartolo Santos, Coordinator, Peter Alexander, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.